よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (46 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
1
2
3
4
5
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
2. 引用文献
1.
GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33
bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease
Study 2019. Lancet. 2022. 400(10369):2221-2248.
6
7
2.
Bennett JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious
Diseases. 9th ed. Philadelphia: Elsevier 2019.
8
9
3.
Pien BC, et al. The clinical and prognostic importance of positive blood cultures in
adults. Am J Med. 2010. 123(9):819-828.
10
11
4.
Thwaites GE, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet
Infect Dis 2011. 11(3):208-222.
12
13
5.
Bai AD, et al. Management of Staphylococcus aureus bacteremia in adults. CMAJ. 2019.
191(135):E967.
14
15
16
6.
Bai AD, et al. Clinical predictors and clinical prediction rules to estimate initial patient risk
for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review
and meta-analysis. Clin Microbiol Infect. 2017. 23(12):900-906.
17
18
7.
Government of South Australia. Staphylococcus aureus Bacteraemia Management
Clinical Guideline. Version 2.0. 2023.
19
20
8.
Coburn B, et al. Does this adult patient with suspected bacteremia require blood
cultures? JAMA. 2012. 308:502-511.
21
22
9.
Lam JC, et al. The Golden Grapes of Wrath - Staphylococcus aureus Bacteremia: A
Clinical Review. Am J Med. 2023. 136(1):19-26.
23
24
25
10. Li J, et al. Comparison of cefazolin versus oxacillin for treatment of complicated
bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents
Chemother. 2014. 58(9):5117-5124.
26
27
28
11. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本
TDM 学会. 2022. at
https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
29
30
31
12. Liu C, et al. Clinical practice guidelines by the infectious diseases society of america for
the treatment of methicillin-resistant Staphylococcus aureus infections in adults and
children. Clin Infect Dis. 2011. 52(3):e18-55.
32
33
13. Figueroa DA, et al. Safety of high-dose intravenous daptomycin treatment: three-year
cumulative experience in a clinical program. Clin Infect Dis. 2009. 49(2):177-180.
34
35
14. Cetinkaya Y, et al. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000. 13:686707.
36
37
38
15. Hayakawa K, et al. High rate of multidrug-resistant organism colonization among
patients hospitalized overseas highlights the need for preemptive infection control. Am J
Infect Control. 2016. 44(11):e257-e259.
39
40
16. 厚生労働省 バンコマイシン耐性腸球菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-14-01.html.)
41
42
17. 薬剤耐性ワンヘルス動向調査年次報告書 2024.
https://www.mhlw.go.jp/content/10900000/001447793.pdf
46
1
2
3
4
5
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
2. 引用文献
1.
GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33
bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease
Study 2019. Lancet. 2022. 400(10369):2221-2248.
6
7
2.
Bennett JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious
Diseases. 9th ed. Philadelphia: Elsevier 2019.
8
9
3.
Pien BC, et al. The clinical and prognostic importance of positive blood cultures in
adults. Am J Med. 2010. 123(9):819-828.
10
11
4.
Thwaites GE, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet
Infect Dis 2011. 11(3):208-222.
12
13
5.
Bai AD, et al. Management of Staphylococcus aureus bacteremia in adults. CMAJ. 2019.
191(135):E967.
14
15
16
6.
Bai AD, et al. Clinical predictors and clinical prediction rules to estimate initial patient risk
for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review
and meta-analysis. Clin Microbiol Infect. 2017. 23(12):900-906.
17
18
7.
Government of South Australia. Staphylococcus aureus Bacteraemia Management
Clinical Guideline. Version 2.0. 2023.
19
20
8.
Coburn B, et al. Does this adult patient with suspected bacteremia require blood
cultures? JAMA. 2012. 308:502-511.
21
22
9.
Lam JC, et al. The Golden Grapes of Wrath - Staphylococcus aureus Bacteremia: A
Clinical Review. Am J Med. 2023. 136(1):19-26.
23
24
25
10. Li J, et al. Comparison of cefazolin versus oxacillin for treatment of complicated
bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents
Chemother. 2014. 58(9):5117-5124.
26
27
28
11. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本
TDM 学会. 2022. at
https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
29
30
31
12. Liu C, et al. Clinical practice guidelines by the infectious diseases society of america for
the treatment of methicillin-resistant Staphylococcus aureus infections in adults and
children. Clin Infect Dis. 2011. 52(3):e18-55.
32
33
13. Figueroa DA, et al. Safety of high-dose intravenous daptomycin treatment: three-year
cumulative experience in a clinical program. Clin Infect Dis. 2009. 49(2):177-180.
34
35
14. Cetinkaya Y, et al. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000. 13:686707.
36
37
38
15. Hayakawa K, et al. High rate of multidrug-resistant organism colonization among
patients hospitalized overseas highlights the need for preemptive infection control. Am J
Infect Control. 2016. 44(11):e257-e259.
39
40
16. 厚生労働省 バンコマイシン耐性腸球菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-14-01.html.)
41
42
17. 薬剤耐性ワンヘルス動向調査年次報告書 2024.
https://www.mhlw.go.jp/content/10900000/001447793.pdf
46